Etiology and pathogenesis of Alzheimer's disease

American Journal of Health-System Pharmacy

Volumn 55, Issue 21 SUPPL., 1998, Pages

  Farlow, Martin R ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Diagnosis; Genetics; Geriatrics; Research

Indexed keywords

AGING; ALZHEIMER DISEASE; BRAIN DISEASE; CONFERENCE PAPER; GENETIC RISK; GENETICS; HUMAN; NEUROPATHOLOGY; NEUROTRANSMITTER RELEASE; PATHOGENESIS; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

EID: 0032213765     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.suppl_2.s5     Document Type: Conference Paper

References (32)

1. Geldmacher DS, Whitehouse PJ Jr. Differential diagnosis of Alzheimer's disease. Neurology. 1997; 48(suppl 6):S2-9.
2. Evans DA, Funkenstein HH, Albert MS et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA. 1989; 262:2551-6.
3. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand. 1987; 76:465-79.
4. Prusiner SB, Hsiao KK. Human prion diseases. Ann Neurol. 1994; 35:385-95.
5. Kalra S, Bergeron C, Lang AE. Lewy body disease and dementia: a review. Arch Intern Med. 1996; 156:487-93.
6. Morris JC. Differential diagnosis of Alzheimer's disease. Clin Geriatr Med. 1994; 10:257-76.
7. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-98.
8. Folstein M, Anthony JC, Parhad I et al. The meaning of cognitive impairment in the elderly. J Am Geriatr Soc. 1985; 33:228-35.
9. Inouye SK, Albert MS, Mohs R et al. Cognitive performance in a high-functioning community-dwelling elderly population. J Gerontol. 1993; 48:M146-51.
10. Crum RM, Anthony JC, Bassett SS et al. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA. 1993; 269:2386-91.
11. Geldmacher DS, Whitehouse PJ. Evaluation of dementia. N Engl J Med. 1996; 335:330-6.
12. Levy-Lahad E, Bird TD. Genetic factors in Alzheimer's disease: a review of recent advances. Ann Neurol. 1996; 40:829-40.
13. Hardy J. New insights into the genetics of Alzheimer's disease. Ann Med. 1996; 28:255-8.
14. Farlow MR. Alzheimer's disease: clinical implications of the apolipoprotein E genotype. Neurology. 1997; 48(suppl 6):S30-4.
15. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261:921-3.
16. Farlow MR, Lahiri DK, Brashear A et al. Metrifonate in the symptomatic treatment of Alzheimer's disease: influence of apolipoprotein E genotype. Neurology. 1998; 50:A88. Abstract.
17. Farlow MR, Lahiri DK, Poirier J et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 1998; 50:669-77.
18. Peskind ER. Neurobiology of Alzheimer's disease. J Clin Psychiatry. 1996; 57(suppl 14):5-8.
19. Adams C. Alzheimer's disease research: a game of connect the dots. Gerontology. 1997; 43:8-19.
20. Cleveland DW, Hwo S-Y, Kirschner MW. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol. 1977; 116:207-25.
21. Trojanowski JQ, Lee VM-Y. Phosphorylation of neuronal cytoskeletal proteins in Alzheimer's disease and Lewy body dementias. Ann N Y Acad Sci. 1994; 747:92-109.
22. Strittmatter WJ, Saunders AM, Goedert M et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A. 1994; 91:11183-6.
23. Strittmatter WJ, Weisgraber KH, Huang DY et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90:8098-102.
24. Bales KR, Verina T, Dodel RC et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet. 1997; 17:263-4. Letter.
25. Bauer J, Strauss S, Schreiter-Gasser U et al. Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 1991; 285:111-4.
26. Griffin WST, Stanley LC, Ling C et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989; 86:7611-5.
27. Aisen PS. Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Gerontology. 1997; 43:143-9.
28. Breitner JC, Gau BA, Welsh KA et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994; 44:227-32.
29. Rich JB, Rasmusson DX, Folstein MF et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995; 45:51-5.
30. Hendrie HC. Epidemiology of Alzheimer's disease. Geriatrics. 1997; 52(suppl 2):S4-8.
31. Muir JL. Acetylcholine, aging, and Alzheimer's disease. Pharmacol Biochem Behav. 1997; 56:687-96.
32. Cummings JL, Cyrus PA, Ruzicka BB et al. The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer's disease patients. Neurology. 1998; 50:A250. Abstract.